Late toxicity in survivors from adolescent cancers
dc.contributor.author | Pentheroudakis, George | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Pentheroudakis, George | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:54:28Z | |
dc.date.available | 2018-06-22T09:54:28Z | |
dc.date.issued | 2007 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42366 | |
dc.description.abstract | Nowadays three quarters of adolescents with cancer are cured but half of them experience a late toxic effect of antineoplastic therapy that interferes with their physical and psychosocial health. This review recapitulates late effects associated with radiation therapy, chemotherapy and surgery, reviews risk factors and prognosis and suggests follow-up and management strategies, excluding fertility issues. Adolescents with cancer should be the focus of active clinical research for the optimisation of antineoplastic treatment as well as for breakthroughs in the follow-up, prevention and management of toxic effects. © 2007 Elsevier Ltd. All rights reserved. | en |
dc.language.iso | eng | en |
dc.source | Cancer treatment reviews | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Bleomycin | en |
dc.subject | Cisplatin | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Cytarabine | en |
dc.subject | Doxorubicin | en |
dc.subject | Etoposide | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Mitomycin | en |
dc.subject | Neoplasms | en |
dc.subject | Patient care | en |
dc.subject | Vincristine | en |
dc.subject | Humans | en |
dc.subject | Cancer screening | en |
dc.subject | Cancer survival | en |
dc.subject | Follow up | en |
dc.subject | Paclitaxel | en |
dc.subject | Prognosis | en |
dc.subject | Dexamethasone | en |
dc.subject | Fever | en |
dc.subject | Pneumonia | en |
dc.subject | Cancer surgery | en |
dc.subject | Survival rate | en |
dc.subject | Acute granulocytic leukemia | en |
dc.subject | Busulfan | en |
dc.subject | Cancer radiotherapy | en |
dc.subject | Cardiomyopathy | en |
dc.subject | Melphalan | en |
dc.subject | Mitoxantrone | en |
dc.subject | Carmustine | en |
dc.subject | Trastuzumab | en |
dc.subject | Diabetes mellitus | en |
dc.subject | Risk factors | en |
dc.subject | Neurologic disease | en |
dc.subject | Hypertension | en |
dc.subject | Pericarditis | en |
dc.subject | Side effect | en |
dc.subject | Lymph node dissection | en |
dc.subject | Drug toxicity | en |
dc.subject | Risk factor | en |
dc.subject | Cancer | en |
dc.subject | Dyspnea | en |
dc.subject | Incidence | en |
dc.subject | Anthracycline derivative | en |
dc.subject | Gastrointestinal disease | en |
dc.subject | Hepatitis | en |
dc.subject | Ifosfamide | en |
dc.subject | Peripheral neuropathy | en |
dc.subject | Corticosteroid | en |
dc.subject | Heart disease | en |
dc.subject | Diuretic agent | en |
dc.subject | Lung fibrosis | en |
dc.subject | Nitrosourea derivative | en |
dc.subject | Kidney disease | en |
dc.subject | World health | en |
dc.subject | Respiratory failure | en |
dc.subject | Liver fibrosis | en |
dc.subject | Adolescent | en |
dc.subject | Heart failure | en |
dc.subject | Lung disease | en |
dc.subject | Social psychology | en |
dc.subject | Thyroid disease | en |
dc.subject | Lifestyle modification | en |
dc.subject | Coughing | en |
dc.subject | Myopathy | en |
dc.subject | Orthopedic surgery | en |
dc.subject | Medical research | en |
dc.subject | Childhood cancer | en |
dc.subject | Testis cancer | en |
dc.subject | Osteosarcoma | en |
dc.subject | Alcohol withdrawal | en |
dc.subject | Avascular necrosis | en |
dc.subject | Bone marrow hypoplasia | en |
dc.subject | Bone necrosis | en |
dc.subject | Brain disease | en |
dc.subject | Cataract | en |
dc.subject | Connective tissue disease | en |
dc.subject | Digoxin | en |
dc.subject | Dipeptidyl carboxypeptidase inhibitor | en |
dc.subject | Dosimetry | en |
dc.subject | Exercise | en |
dc.subject | Female sterility | en |
dc.subject | Fracture | en |
dc.subject | Immune deficiency | en |
dc.subject | Late toxicity | en |
dc.subject | Lymphocele | en |
dc.subject | Male sterility | en |
dc.subject | Mood disorder | en |
dc.subject | Muscle necrosis | en |
dc.subject | Myelodysplasia | en |
dc.subject | Myofibrosis | en |
dc.subject | Nephrosclerosis | en |
dc.subject | Neuropathic pain | en |
dc.subject | Osteolysis | en |
dc.subject | Physical capacity | en |
dc.subject | Postoperative pain | en |
dc.subject | Prosthesis loosening | en |
dc.subject | Radiation dose fractionation | en |
dc.subject | Retrograde ejaculation | en |
dc.subject | Skin atrophy | en |
dc.subject | Skin fibrosis | en |
dc.subject | Skin pigmentation | en |
dc.subject | Smoking cessation | en |
dc.subject | Spinal cord disease | en |
dc.subject | Teniposide | en |
dc.title | Late toxicity in survivors from adolescent cancers | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/j.ctrv.2007.06.002 | |
dc.description.volume | 33 | |
dc.description.issue | 7 | |
dc.description.startingpage | 656 | |
dc.description.endingpage | 663 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Pentheroudakis, George [0000-0002-6632-2462] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-6632-2462 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |